[go: up one dir, main page]

EE04750B1 - HIV-proteaasi inhibiitorite valmistamismeetod - Google Patents

HIV-proteaasi inhibiitorite valmistamismeetod

Info

Publication number
EE04750B1
EE04750B1 EEP200000568A EEP200000568A EE04750B1 EE 04750 B1 EE04750 B1 EE 04750B1 EE P200000568 A EEP200000568 A EE P200000568A EE P200000568 A EEP200000568 A EE P200000568A EE 04750 B1 EE04750 B1 EE 04750B1
Authority
EE
Estonia
Prior art keywords
preparation
protease inhibitors
hiv protease
hiv
inhibitors
Prior art date
Application number
EEP200000568A
Other languages
English (en)
Estonian (et)
Inventor
Al-Farhan Emile
D. Deininger David
Mcghie Stephen
O`Callaghan John
Stuart Robertson Mark
Rodgers Keith
John Rout Stephen
Singh Hardev
Dennis Tung Roger
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000568A publication Critical patent/EE200000568A/xx
Publication of EE04750B1 publication Critical patent/EE04750B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
EEP200000568A 1998-03-20 1999-03-18 HIV-proteaasi inhibiitorite valmistamismeetod EE04750B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9805898.5A GB9805898D0 (en) 1998-03-20 1998-03-20 Process for the sythesis of hiv protease inhibitors
PCT/GB1999/000852 WO1999048885A1 (en) 1998-03-20 1999-03-18 Process for the synthesis of hiv protease inhibitors

Publications (2)

Publication Number Publication Date
EE200000568A EE200000568A (et) 2002-02-15
EE04750B1 true EE04750B1 (et) 2006-12-15

Family

ID=10828884

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000568A EE04750B1 (et) 1998-03-20 1999-03-18 HIV-proteaasi inhibiitorite valmistamismeetod

Country Status (31)

Country Link
US (1) US6281367B1 (pt)
EP (1) EP1066276B1 (pt)
JP (1) JP3363439B2 (pt)
KR (1) KR100555278B1 (pt)
CN (1) CN1308319C (pt)
AP (1) AP1226A (pt)
AT (1) ATE242772T1 (pt)
AU (1) AU751534B2 (pt)
BR (1) BR9908970A (pt)
CA (1) CA2324217C (pt)
CZ (1) CZ299193B6 (pt)
DE (1) DE69908761T2 (pt)
DK (1) DK1066276T3 (pt)
EA (1) EA003022B1 (pt)
EE (1) EE04750B1 (pt)
ES (1) ES2203090T3 (pt)
GB (1) GB9805898D0 (pt)
HR (1) HRP20000609B1 (pt)
HU (1) HUP0105439A3 (pt)
ID (1) ID26587A (pt)
IL (1) IL138127A (pt)
IS (1) IS2273B (pt)
NO (1) NO317648B1 (pt)
NZ (1) NZ506563A (pt)
PL (1) PL201810B1 (pt)
PT (1) PT1066276E (pt)
RS (1) RS49954B (pt)
SK (1) SK283939B6 (pt)
TR (1) TR200002698T2 (pt)
WO (1) WO1999048885A1 (pt)
ZA (1) ZA200004482B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100296463B1 (ko) 1992-08-25 2001-10-24 죤 에이치. 뷰센 레트로바이러스프로테아제저해제로서유용한히드록시에틸아미노술폰아미드
EP2314563A3 (en) * 1999-12-23 2012-04-04 Ampac Fine Chemicals LLC Improved preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
US6548706B2 (en) * 1999-12-23 2003-04-15 Aerojet Fine Chemicals Llc Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
SI1567529T2 (sl) 2002-05-16 2021-08-31 Janssen Sciences Ireland Unlimited Company Psevdopolimorfne oblike zaviralca HIV proteaze
BRPI0417272B8 (pt) * 2003-12-23 2021-05-25 Janssen R&D Ireland processo para a preparação de (3r, 3as, 6ar)-hexahidrofuro [2,3-b] furan-3-il (1s, 2r)-3-[[(4-aminofenil) sulfonil] (isobutil) amino]-1-benzil-2-hidroxipropilcarbamato
ME01059B (me) 2003-12-23 2012-10-20 Janssen Sciences Ireland Uc Proces za pripremanje (3r,3as,6ar)-heksahidrofuro [2,3-b] furan-3-il (1s,2r)-3-[[(4-aminofenil) sulfonil] (izobutil) amino]-1-benzil-2- hidroksipropilkarbamata
TWI482775B (zh) 2008-09-01 2015-05-01 Tibotec Pharm Ltd 用於製備（３ｒ，３ａｓ，６ａｒ）－六氫呋喃并〔２，３－ｂ〕呋喃－３－基（１ｓ，２ｒ）－３－〔〔（４－胺基苯基）磺醯基〕（異丁基）胺基〕－１－苯甲基－２－羥基丙基胺基甲酸酯之方法
SMT201800290T1 (it) 2010-01-27 2018-07-17 Viiv Healthcare Co Terapia antivirale
US8877947B2 (en) 2010-09-10 2014-11-04 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
CN111233794A (zh) * 2020-03-27 2020-06-05 江巨东 一种安普那韦的精制方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
KR100296463B1 (ko) * 1992-08-25 2001-10-24 죤 에이치. 뷰센 레트로바이러스프로테아제저해제로서유용한히드록시에틸아미노술폰아미드
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease

Also Published As

Publication number Publication date
BR9908970A (pt) 2000-11-28
JP3363439B2 (ja) 2003-01-08
NO20004664L (no) 2000-09-19
HRP20000609B1 (en) 2006-05-31
JP2002507609A (ja) 2002-03-12
AU2947599A (en) 1999-10-18
HK1032047A1 (en) 2001-07-06
YU55900A (sh) 2003-02-28
AU751534B2 (en) 2002-08-22
HUP0105439A3 (en) 2002-08-28
IL138127A0 (en) 2001-10-31
NO317648B1 (no) 2004-11-29
NZ506563A (en) 2003-05-30
CN1308319C (zh) 2007-04-04
AP2000001911A0 (en) 2000-09-30
EP1066276B1 (en) 2003-06-11
EA003022B1 (ru) 2002-12-26
ATE242772T1 (de) 2003-06-15
CZ20003457A3 (cs) 2001-04-11
ZA200004482B (en) 2001-11-28
EA200000859A1 (ru) 2001-04-23
US6281367B1 (en) 2001-08-28
CZ299193B6 (cs) 2008-05-14
IS2273B (is) 2007-07-15
SK13732000A3 (sk) 2001-08-06
DE69908761T2 (de) 2004-02-19
CA2324217C (en) 2008-02-19
AP1226A (en) 2003-11-21
CA2324217A1 (en) 1999-09-30
ES2203090T3 (es) 2004-04-01
HUP0105439A2 (en) 2002-06-29
WO1999048885A1 (en) 1999-09-30
RS49954B (sr) 2008-09-29
SK283939B6 (sk) 2004-05-04
CN1293668A (zh) 2001-05-02
KR20010042022A (ko) 2001-05-25
PL201810B1 (pl) 2009-05-29
TR200002698T2 (tr) 2000-12-21
ID26587A (id) 2001-01-18
IS5605A (is) 2000-08-29
HRP20000609A2 (en) 2001-04-30
PL342602A1 (en) 2001-06-18
KR100555278B1 (ko) 2006-03-03
DE69908761D1 (de) 2003-07-17
GB9805898D0 (en) 1998-05-13
NO20004664D0 (no) 2000-09-19
DK1066276T3 (da) 2003-10-06
PT1066276E (pt) 2003-10-31
EP1066276A1 (en) 2001-01-10
EE200000568A (et) 2002-02-15
IL138127A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
NO20012980D0 (no) Proteaseinhibitorer
CY2007029I1 (el) Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
NO995433D0 (no) Protease-inhibitorer
DE69823178D1 (de) Serine protease inhibitoren
DK1085981T3 (da) Fremgangsmåde til emballering
IT1315269B1 (it) Metodo per la preparazione di 5-cianoftalide
NO995435D0 (no) Protease-inhibitorer
NO995434L (no) Proteaseinhibitorer
NO995268D0 (no) Proteaseinhibitorer
EE200100383A (et) L-fenüülefriinvesinikkloriidi valmistamise meetod
DE59806475D1 (de) Urokinase-inhibitoren
EE04750B1 (et) HIV-proteaasi inhibiitorite valmistamismeetod
FI20000553L (fi) Proteaasi-inhibiittoreina käyttökelpoisten 4-hydroksi-2-oksopyraanijohdannaisten valmistusmenetelmä
FI963054L (fi) Menetelmä HIV-proteaasi-inhibiittoreiden valmistamiseksi
DK0987356T3 (da) Fremgangsmåde til trækning
FI960206A7 (fi) Menetelmä HIV-proteaasi-inhibiittoreiden valmistamiseksi
FI960184L (fi) Menetelmä HIV-proteaasi-inhibiittoreiden valmistamiseksi
TR199800403A3 (tr) a-Bromo-laktam türevlerinin hazirlanmasi için yöntem.
DZ2815A1 (fr) Inhibiteurs de protéase.
FI20002262A0 (fi) Menetelmä proteiinin rakenteen muuttamiseksi
DK1077945T3 (da) Isoquinoliner som urokinaseinhibitorer
EE9900404A (et) Arüülaminotriasolopüridiinide valmistamise meetod
EE04114B1 (et) HIV-proteaasi inhibiitorid
EE04465B1 (et) Vaheühendid HIV-proteaasi inhibiitorite valmistamiseks ja HIV-proteaasi inhibiitorite valmistamismeetodid

Legal Events

Date Code Title Description
HK1A Erratum in gazette
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20100318